查詢結果分析
相關文獻
- 蘇力菌素對大鼠口服及肺毒性之評估
- 本土綠殭菌對大鼠急毒性與致病性之安全評估
- 大鼠氣管內重覆暴露於氯化鎘之亞急毒性研究
- 以沙門氏桿菌及枯草桿菌偵測蘇力菌素之遺傳毒性
- 農藥免賴得致胚胎畸形及其測試方法之建立
- Cytotoxicity of Food Mycotoxins, Natural Food Additives and Natural Aromas in Primary Cultured Rat Hepatocytes
- 當歸補血湯對缺血性大鼠被動迴避學習反應障礙之影響
- Tissue Plasminogen Activator Reduces Intraperitoneal Adhesion after Intestinal Resection in Rats
- Effect of Angiotension Converting Enzyme Inhibition on Renal Response to Atrial Natriuretic Factor in Rats
- 實驗大鼠和小鼠的人畜共通傳染病
頁籤選單縮合
| 題 名 | 蘇力菌素對大鼠口服及肺毒性之評估=Acute Oral and Pulmonary Toxicity of Thuringiensin in Rats |
|---|---|
| 作 者 | 蔡三福; 廖俊旺; 王順成; | 書刊名 | 中華民國獸醫學會雜誌 |
| 卷 期 | 24:3 1998.09[民87.09] |
| 頁 次 | 頁203-211 |
| 分類號 | 437.23 |
| 關鍵詞 | 蘇力菌素; 口服毒性; 肺毒性; 大鼠; Thuringiensin; Oral toxicity; Pulmonary toxicity; Rat; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 本研究主要目的乃針對蘇力菌素（ thuringiensin ）開發過程中使用不同萃取物 （ cetylpyridinium chloride, CPC 或澱粉萃取物）所純化出之產物對哺乳動物之急毒性 評估，並比較其口服及肺急毒性之差異。 以單一劑量胃管投予大鼠每公斤體重 0，10，30 ， 50， 70 及 90 mg/kg 之5.87%蘇力菌素（以 CPC 萃取）或 0， 500 及 1,090 mg/kg之 7.20% 蘇力菌素（以澱粉萃取），並以 0 及 250 mg/kg CPC 作為萃取物對照組，投藥後連 續觀察 21 天。結果顯示 5.87% 蘇力菌素及 CPC 組，處理鼠隻呈現遲鈍、皮毛粗剛、抽搐 或死亡等症狀，5.87% 蘇力菌素組之口服半致死劑量（ LD �t）為 53.9 mg/kg。 而 7.20% 蘇力菌素組則無任何中毒症狀， 可知以澱粉萃取製成之 7.20% 蘇力菌素為一較安全製劑， 本實驗另以此劑型進一步探討其肺急毒性。 以氣管投予大鼠每公斤體重 0，5，20， 50 及 100 mg/kg 之 7.20% 蘇力菌素並連續觀察 21 天。 於投藥後大鼠出現明顯呼吸音，體重及 體溫降低、俯臥、皮毛粗剛及死亡等現象，其 LD �t為 71.8 mg/kg。 肺急性處理死亡鼠隻 之肺臟出現明顯充出血，組織切片下呈現瀰漫性出血、水腫及氣腫、小支氣管炎及肺泡局部 壞死等傷害，經 21 天後存活之鼠隻肺臟則有局部纖維化病變。綜合以上結果顯示， 僅含 CPC 或以 CPC 萃取之 5.87% 蘇力菌素對大鼠均具有較強之口服急毒性，而以澱粉萃取之 7.20% 蘇力菌素則否，其對大鼠口服急毒性大於 1,090 mg/kg， 但其具有急性肺毒性造成 肺部慢性纖維化等傷害。故商品化之蘇力菌素產品應避免製成粉劑劑型，改以粒劑或水溶性 粒劑等劑型，可降低對人類及動物之潛在毒性。 |
| 英文摘要 | Mammalian acute oral and pulmonary toxicities of rats to thuringiensin products from different protocols such as extracts from cetylpyridinium chloride, and starch-extracted were investigated in this study. Rats were gavaged individually with dosage as follows: 0, 10, 30, 50, 70 and 90 mg/kg of 5.87% thuringiensin (CPC-extracted) per body weight, or 0, 500 and 1,090 mg/kg of 7.20% thuringiensin (starch-extracted), 0 and 250mg/kg of CPC as extracted-material control group. The observation period was set for 21 days. Results revealed that 5.87% thuringiensin-and CPC-treated animals showed signs of dullness, rough hair, convulsion or eventually died. Unlike 5.87% thuringiensin-and CPC-treated animals, the 7.20% thuringiensin treated showed no significant toxic sign after treatment. The calculated oral LD�t of 5.87% thuringiensin product was 53.9 mg/kg based on our results. According to the oral toxicity, the LD�tof 7.20% thuringiensin was greater than 1,090mg/kg, and then evaluate the pulmonary toxicity. Intratracheal instillation was applied with 0, 5, 20, 50 and 100 mg/kg per body weight of 7.20% thuringiensin product for 21 days. Respiratory-rales, hypothermia, prone, rough hair, decrease body weight gain and death were observed after dosing. The pulmonary LD�tS calculated was 71.8 mg/kg. At necropsy, effected lungs were exhibited remarkable hyperemia and hermorrhage on the surface of thuringiensin treated rats. Pathological findings revealed symptoms such as diffused hemorrhage, edema, emphysema, brochiolitis, and alveolar necrosis in the dead animals, and focal fibrotic lesions in the survival rats at the end of experiment. In conclusion, both of 5.87% thuringiensin product and CPC were harmful to rats by oral uptake in this study. The 7.20% thuringiensin did not cause acute oral lethality until the dosage reached 1,090 mg/kg or above, but induced obviously pulmonary toxicity in tested rats. The best strategy to minimize the risk of pulmonary toxicity on mammals would be to formulate it in a granule form or soluble form. |
本系統中英文摘要資訊取自各篇刊載內容。